Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![USCorpFilings Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1859110030752313345.png) SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4253 followers
Created: 2025-07-07 12:30:08 UTC

$DNLI Clinical Trials:

On July 7, 2025, Denali Therapeutics announced that the U.S. FDA accepted its Biologics License Application for tividenofusp alfa to treat Hunter syndrome, granting it Priority Review.




XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942199453030776924/c:line.svg)

**Related Topics**
[sec](/topic/sec)
[$dnli](/topic/$dnli)

[Post Link](https://x.com/USCorpFilings/status/1942199453030776924)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

USCorpFilings Avatar SEC Filings Digest @USCorpFilings on x 4253 followers Created: 2025-07-07 12:30:08 UTC

$DNLI Clinical Trials:

On July 7, 2025, Denali Therapeutics announced that the U.S. FDA accepted its Biologics License Application for tividenofusp alfa to treat Hunter syndrome, granting it Priority Review.

XXX engagements

Engagements Line Chart

Related Topics sec $dnli

Post Link

post/tweet::1942199453030776924
/post/tweet::1942199453030776924